所有图片(1)

主要文件

COO原产地证书/COA分析证书

查看所有文档

安全信息

安全和法规

1435003

USP

甲基强的松龙

Name: 甲基强的松龙
Brand: USP

United States Pharmacopeia (USP) Reference Standard

别名:

6α-甲基泼尼松龙, 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮, 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮, 甲基强的松龙, 甲基泼尼松龙

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₂H₃₀O₅

CAS号:

83-43-2

分子量:

374.47

Beilstein:

2340300

MDL编号:

MFCD00010591

UNSPSC代码:

41116107

PubChem化学物质编号:

329750457

NACRES:

NA.24

推荐产品

Slide 1 of 10

1 of 10

M1750000

甲基强的松龙

Supelco

PHR1717

甲基强的松龙

USP

1437009

Methylprednisolone hemisuccinate

Sigma-Aldrich

M0639

6α-甲基泼尼松龙

BP248

甲基强的松龙

M1755200

Methylprednisolone hydrogen succinate

USP

1436006

醋酸甲泼尼龙

Y0001101

干扰素β-1A

Supelco

PHR1718

醋酸甲泼尼龙

Supelco

46436

6α-甲基泼尼松龙

等级

pharmaceutical primary standard

API类

methylprednisolone

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI key

VHRSUDSXCMQTMA-PJHHCJLFSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Methylprednisolone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Methylprednisolone Sodium Succinate for Injection
Methylprednisolone Tablets

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他说明

Sales restrictions may apply.

警示用语：

Danger

危险声明

H360FD,H373

预防措施声明

P202 - P260 - P280 - P308 + P313 - P405 - P501

危险分类

Repr. 1B - STOT RE 2

靶器官

Adrenal gland,Immune system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Fungal infections associated with contaminated methylprednisolone injections.

Carol A Kauffman et al.

The New England journal of medicine, 368(26), 2495-2500 (2012-10-23)

Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia.

Amy L Samuels et al.

British journal of haematology, 165(1), 57-66 (2014-01-25)

Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to

Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease.

Tyree H Kiser et al.

American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)

Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Robert J Fox et al.

Neurology, 82(17), 1491-1498 (2014-04-01)

RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients

Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy.

M Toledano et al.

Neurology, 82(18), 1578-1586 (2014-04-08)

To evaluate a trial of immunotherapy as an aid to diagnosis in suspected autoimmune epilepsy. We reviewed the charts of 110 patients seen at our autoimmune neurology clinic with seizures as a chief complaint. Twenty-nine patients met the following inclusion

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

主要文件

安全信息

甲基强的松龙

United States Pharmacopeia (USP) Reference Standard

About This Item

推荐产品

属性

等级

API类

制造商/商品名称

应用

包装形式

SMILES字符串

InChI

InChI key

基因信息

说明

一般描述

应用

分析说明

其他说明

相关产品

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

靶器官

储存分类代码

WGK

法规信息

文件

分析证书(COA)

已有该产品？

同行评审论文

技术服务